AFMD - CONSENSUS CO - Affimed

Affimed leverages its unique ROCK platform to activate NK cells against tumors, providing significant pricing power despite a low demand price threshold. The team consists of top immunologists attracted by the cutting-edge scientific foundation. The share price history with the metric is shown below. Future growth depends on the success of clinical trials and the ability to capture the niche before expansion by major pharma behemoths.

Affimed is developing the innovative ROCK platform, creating incubator antibodies to activate the immune response for the therapy of lymphomas and tumors. The dynamics of the consensus target price reflect the weighted average view of experts on the business's fair value, allowing investors to assess the alignment of market expectations and the risk of overpayment when analyzing trends within this consensus target price.